关于多发性硬化症新型治疗的最新消息:从惨淡的失败到闪闪发光的成功
Bruce Cree1, Hans-Peter Hartung2,3,4,5
1Professor of Clinical Neurology, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA.
Current opinion in neurology
|March 26, 2025
概括
针对多发性硬化症 (MS) 的新疗法正在临床试验中,其目标是逐渐残疾和髓修复. 有些看起来很有前途,为MS患者提供新的治疗选择的希望.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 免疫学 免疫学 免疫学
背景情况:
- 多发性硬化症 (MS) 是一种慢性神经系统疾病,其特点是逐渐残疾.
- 现有的治疗方法主要用于治疗复发性MS,对于渐进性MS的治疗选择有限.
- 对于针对髓修复和神经保护的疗法有着至关重要的需求.
研究的目的:
- 审查目前正在进行临床研究的新兴多发性硬化症 (MS) 疗法.
- 分类针对多发性硬化病理学各个方面的新型治疗策略.
- 为了确定进展性多发性硬化和治疗阻断性疾病的有希望的治疗方法.
主要方法:
- 对新型多发性硬化疗法临床试验的系统审查.
- 将67项已选定的临床试验分类为不同的治疗组.
- 对试验结果的分析,重点关注疗效和安全终点.
主要成果:
- 布鲁顿的氨酸激酶抑制剂 (例如,托莱布鲁丁尼) 在非复发性二级渐进性MS中减缓残疾进展方面表现出有效性.
- 转基因治疗,免疫调节剂,B细胞治疗,补充剂,微生物群影响剂和细胞导向疗法正在研究中.
- 在其第3期试验中,simvastatin未能证明对残疾有显著影响.
结论:
- 目前正在探索多种治疗策略,以对抗渐进性残疾,促进髓修复,并在MS中提供神经保护.
- 一些临床试验的成功完成表明,对于挑战性多发性硬化方面的新治疗选择有潜力.
- 新兴疗法为改善治疗耐药性多发性硬化和疾病进展形式的管理提供了希望.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...